Design Therapeutics (NASDAQ:DSGN) just reported results for the fourth quarter of 2023.
- Design Therapeutics reported earnings per share of -21 cents. This was above the analyst estimate for EPS of -31 cents.
- The company did not report any revenue for the quarter.